Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients

Viral Immunology

Volumn 23, Issue 3, 2010, Pages 329-334

  Kositanont, Uraiwan ^a   Wongsurakiat, Phunsup ^a   Pooruk, Phisanu ^a   Maranetra, Nanta ^a   Puthavathana, Pilaipan ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; TRIPLE VACCINE; VIRUS ANTIBODY; VITAMIN B GROUP;

ACUTE RESPIRATORY TRACT DISEASE; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOASSAY; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; RESPIRATORY DISTRESS; SEASONAL INFLUENZA; SEROCONVERSION; SEROLOGY; VIRUS NEUTRALIZATION; BLOOD; CASE CONTROL STUDY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; LONGITUDINAL STUDY; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS;

AVES; INFLUENZA A VIRUS; INFLUENZA B VIRUS; ORTHOMYXOVIRIDAE;

AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CROSS REACTIONS; DOUBLE-BLIND METHOD; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONGITUDINAL STUDIES; NEUTRALIZATION TESTS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77954147554     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0082     Document Type: Article

References (26)

1. Burlington DB, Wright PF, van Wyke KL, Phelan MA, and Mayner RE: Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985;21: 847-849.
2. Brownstein JS, Kleinman KP, and Mandl KD: Identifying pediatric age groups for influenza vaccination using a realtime regional surveillance system. Am J Epidemiol 2005;162: 686-693.
3. Claas EC, Osterhaus AD, van Beek R, et al.: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-477.
4. Gioia C, Castilletti C, Tempestilli M, et al.: Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008;14:121-128.
5. Gocnyk M, Fislova T, Mucha V, Sladkova T, Russ G, Kostolansky F, and Vareckova E: Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J Gen Virol 2008;89:958-967.
6. Gocnyk M, Fislova T, Sladkova T, Mucha V, Kostolansky F, and Vareckova E: Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol 2007;88: 951-955.
7. Katz JM, Lim W, Bridges CB, et al.: Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999;180:1763-1770.
8. Kilbourne ED: Influenza pandemics of the 20th century. Emerg Infect Dis 2006;12:9-14.
9. Kitphati R, Pooruk P, Lerdsamran H, et al.: Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans. Clin Vaccine Immunol 2009;16: 978-981.
10. Kositanont U, Kanyok R, Wasi C, Wongsurakiat P, Suthamsmai T, and Maranetra N: Occurrence and protective level of influenza infections using serology in patients with COPD in vaccination study. J Med Assoc Thai 2004;87: 964-969.
11. Monto AS and Kendal AP: Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973;1:623-625.
12. Nguyen HH, Moldoveanu Z, Novak MJ, et al.: Heterosubtypic immunity to lethal influenza A virus infection is associated with virus specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 1999;254:50-60.
13. Nguyen HH, Ginkel van FW, Vu HL, McGhee JR, and Mestecky J: Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001;183:368-376.
14. North Dakota Department of Health, Division of Disease Control: 2003-2004 Influenza Season Summary. http://www .ndhealth.gov/disease/Documents/ pump%20handle/01-09 .pdf
15. Okuno Y, Isegawa Y, Sasao F, and Ueda S: A common neutralizing epitope conserved between the hemagglutinin of influenza A virus H1 and H2 strains. J Virol 1993;67:2552-2558.
16. Remarque EJ, Bruijn de IA, Boersma WJ, Masurel N, and Ligthart GJ: Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 1998;55:82-87.
17. Rowe T, Abernathy RA, Hu-Primmer J, et al.: Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-943.
18. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, and Webby RJ: Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007;4:e59:265-272.
19. Tang JW, Karry LK, and Chan PKS: Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. J Med Virol 2008;80:1992-1996.
20. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, and Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-1351.
21. Viboud C, Grais RF, Lafont BA, Miller MA, and Simonsen L: Multinational impact of the 1968 Hong Kong influenza pandemic: Evidence for a smoldering pandemic. J Infect Dis 2005;192:233-248.
22. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, and Charoenratanakul S: Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;125:2011-2020. (Pubitemid 38788164)
23. World Health Organization: WHO manual on animal influenza diagnosis and surveillance. Geneva, World Health Organization, 2002 (document WHO/CDS/CSR/NCS/ 2002.5), pp 28-39.
24. World Health Organization: Cumulative number of confirmed human cases of avian influenza A/(H5N1), 2009. http://www.who.int/csr/disease/avian-influenza/ country/ cases-table-2009-04-08/en/index.html
25. World Health Organization: Influenza (seasonal) fact sheet No 211, 2009. http://www.who.int/mediacentre/factsheets/ fs211/en/index.html
26. Yu H, Gao Z, Feng Z, et al.: Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 2008;3: e2985.